Press Room

39th Symposium on Particulate Preparations and Designs

Start
Tuesday, November 29, 2022 - 09:00
End
Wednesday, November 30, 2022 - 18:00
Location: Himeji, Japan

 

Schedule your meeting today with Yasushi Usuda - Regional Sales Director
yasushi-usuda-photo
 

 

 

Let’s discuss your project together.

 

Yasushi Usuda will be a speaker at the symposium.

 

  • Title: Dispersome Technology – A new tool for solubility enhancement 
  • Abstract: The Dispersome® technology is based on the use of whey protein isolate to create so called Dispersomes® – a unique amorphous composition of small molecule drugs and proteins shown to be superior in terms of amorphous stabilization, dissolution and solubility enhancement as well as improvements in bioavailability, achieving drug loadings of 50 wt% and higher. The technology is offered together with ASD-HIPROS, Hovione’s Intelligent Proprietary Screening, is the most advanced and accurate tool to identify Amorphous Solid Dispersion (ASD) formulations by Spray Drying with maximum performance and stability. To further enhance the chances of identifying the best performing ASD formulation we have included Dispersome® into ASD-HIPROS to expand formulation options beyond polymeric excipients.

 

Schedule a meeting today!

 

 

Also in the Press Room

See All

Continuous Tableting (CT) is defined as continuous manufacturing of oral dose drugs, specifically tablets. As per ICH's Q13 definition1, a continuous manufacturing process in the pharmaceutical industry comprises at least two unit operations integrated from a mechanical and software perspective. There is a wide combination of possible CT process configurations that are dependent on the needs of the intended product formulation and each of the individual unit operations that constitute the process train can be continuous, semi-continuous, or batch processes. The typical manufacturing processes for tablet formulation are direct compression (DC), dry granulation (DG) and wet granulation (WG)2 - details on these manufacturing processes are beyond the scope of this article, so the interested reader is directed to relevant literature. The actual implementation of CT technology in a facility can broadly vary depending on the level of desired integration and automation. Process trains can be designed to be flexible and converted between multiple configurations (e.g. continuous DC, DG and WG), controlled by the end user from one single software and within a single clean room. The other possibility would be for subsections of the CT process to be divided into multiple clean rooms where inprocess materials are transferred between suites via a bin-to-bin approach (e.g. a granulation suite to prepare granules from raw materials followed by continuous DC (CDC) to blend the granules and produce tablets). The level of automation and instrumentation designed into the CT process (typically involving Process Analytical Technologies, PAT) can open the possibility to implement sophisticated control strategies. Key components of a control strategy that need to be considered for CT are material tracking and genealogy, knowledge of the residence time distribution (RTD), and in-process controls (spectroscopic and/or soft sensors based on process parameters). Holistically, these control strategy elements enable the implementation of a material diversion strategy to automatically divert out of specification material from the process. In their most advanced form, control strategies may also enable real time release testing (RTRt) of the final tablet drug product and reduce the off-line analytical burden and the number of operators needed to manage the process.   Read the full article at gmp-journal.com  

Article

Continuous Tableting and the Road to Global Adoption

Mar 04, 2024